Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy;Eficacia y seguridad de la terapia hipoglucemiante oral combinada de glimepirida más metformina en una sola forma farmacéutica en pacientes con diabetes mellitus tipo 2 y falla secundaria a monoterapia con glibenclamida

Revista de Investigacion Clinica

Volumn 56, Issue 3, 2004, Pages 327-333

  González Ortiz, Manuel ^a,c   Martínez Abundis, Esperanza ^a   Guerrero Romero, C Fernando ^b   Ávalos de la Cabada, Cynthia ^c   Bustos Saldaña, C Rafael ^b   Grover Páez, C Fernando ^b   Robles Cervantes, C José Antonio ^b   Rodríguez Morán, C Martha ^b   Castellanos García, C María Cristina ^b   Vidrio Velázquez, Maricela ^d   Peniche Flores, Miguel ^c  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c SA de CV ^*  (Mexico)

^d Laboratorios Silanes SA de CV   (Mexico)

Author keywords

Diabetes mellitus type 2 treatment; Glimepiride; Metformin; Oral antidiabetic drugs combined therapy

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TITRIMETRY; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; TREATMENT FAILURE;

EID: 4544349599     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Estadísticas de mortalidad en México: muertes registradas en el año 2000. Sal Pub Mex 2002; 44: 266-82.
2. Aguilar-Salinas CA, Vázquez-Chávez C, Gamboa-Marrufo R, García-Soto N, Ríos-González JJ, Holguín R, Vela S, Ruiz-Álvarez F, Mayagoitia S. Obesity, diabetes, hypertension, and tobacco consumption in an urban adult Mexican population. Arch Med Res 2001; 32: 446-53.
3. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 2002; 25: 1015-21.
4. Dandona P, Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol 2002; 90: 27G-33G.
5. Matthews DR. The natural history of diabetes-related complications: the UKPDS experience. United Kingdom Prospective Diabetes Study. Diabetes Obes Metab 1999; 1(Suppl. 2): S7-S13.
6. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
7. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
8. Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am 2001; 30: 909-33.
9. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998; 15: 297-303.
10. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. UK Prospective Diabetes Study Group. Diabetes Care 1998; 21: 87-92.
11. Hermann LS, Schersten B, Bitzen PO, Kjellstrom,T, Lindgarde F, Melander A. Therapeutic comparison of metfomin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17: 1100-9.
12. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000; 108(Suppl. 6A): 15S-22S.
13. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25(Suppl. 1): S33-S49.
14. Jeyaseelan L, Rao PSS. Methods of determining sample sizes in clinical trials. Indian Ped 1989; 26: 115-21.
15. Muller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas- a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 1995; 28 (Suppl.): S115-S137.
16. McCall AL. Clinical review of glimepiride. Expert Opin Pharmacother 2001; 2: 699-713.
17. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25-33.
18. Wulffele MG, Kooy A, De Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus; a systematic review. Br J Clin Pharmacol 2002; 53: 549P-550P.
19. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin menotherapy in type 2 diabetic patients. Diabet Med 2001; 18: 828-34.
20. Schneider J. An overview of the safety and tolerance of glimepiride. Horm Metab Res 1996; 28: 413-18.
21. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999; 20: 489-503.